Cargando…

Application of a validated algorithm to estimate the effectiveness and cost of biologics for rheumatoid arthritis in the US pharmacy benefit manager context

BACKGROUND: Several biologic medicines are available to treat rheumatoid arthritis (RA), and they differ in administration method (subcutaneous or intravenous [IV]). We analyzed a pharmacy benefit manager database to estimate claims-based, algorithm-determined effectiveness and cost per effectively...

Descripción completa

Detalles Bibliográficos
Autores principales:	Wu, Ning, Bhurke, Sharvari, Shah, Neel, Harrison, David J
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Dove Medical Press 2015
Materias:	Original Research
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4435053/ https://www.ncbi.nlm.nih.gov/pubmed/25999750 http://dx.doi.org/10.2147/CEOR.S83932

Ejemplares similares

Cost of tumor necrosis factor blockers per patient with rheumatoid arthritis in a multistate Medicaid population
por: Bonafede, Machaon, et al.
Publicado: (2014)

Biologic Cost per Effectively Treated Rheumatoid Arthritis Patient in a Large Managed Care Population: A Retrospective Cohort Study
por: Gu, Tao, et al.
Publicado: (2015)

Clinical Outcomes and Biologic Costs of Switching Between Tumor Necrosis Factor Inhibitors in US Veterans with Rheumatoid Arthritis
por: Cannon, Grant W., et al.
Publicado: (2016)

Effect of Carving in Pharmacy Benefits on Utilization and Costs
por: Parekh, Natasha, et al.
Publicado: (2020)

Benefits of Exercise in Rheumatoid Arthritis
por: Cooney, Jennifer K., et al.
Publicado: (2011)

Tumor Necrosis Factor-Blocker Dose Escalation in Rheumatoid Arthritis Patients in a Pharmacy Benefit Management Setting
por: Blume, Steven W., et al.
Publicado: (2013)

Impact of a specialty pharmacy benefit on rheumatoid arthritis medication adherence and functional status: a continuation study
por: Kozlicki, Miranda, et al.
Publicado: (2019)

Estimation of the Share of Net Expenditures on Insulin Captured by US Manufacturers, Wholesalers, Pharmacy Benefit Managers, Pharmacies, and Health Plans From 2014 to 2018
por: Van Nuys, Karen, et al.
Publicado: (2021)

Administration costs of intravenous biologic drugs for rheumatoid arthritis
por: Soini, Erkki J, et al.
Publicado: (2013)

Indirect costs of rheumatoid arthritis
por: Raciborski, Filip, et al.
Publicado: (2015)

Comparison of Mail-Order With Community Pharmacy in Plan Sponsor Cost and Member Cost in Two Large Pharmacy Benefit Plans
por: Johnsrud, Michael, et al.
Publicado: (2007)

Remission in rheumatoid arthritis: benefit over low disease activity in patient-reported outcomes and costs
por: Radner, Helga, et al.
Publicado: (2014)

Benefits of wrist splinting in patients with rheumatoid arthritis
por: Sadura-Sieklucka, Teresa, et al.
Publicado: (2018)

The Economic Benefit of Remission for Patients with Rheumatoid Arthritis
por: Curtis, Jeffrey R., et al.
Publicado: (2022)

State Medicaid Pharmacy Payments and Their Relation to Estimated Costs
por: Adams, E. Kathleen, et al.
Publicado: (1994)

Estimating Patient-Specific Relative Benefit of Adding Biologics to Conventional Rheumatoid Arthritis Treatment: An Individual Participant Data Meta-Analysis
por: Luo, Yan, et al.
Publicado: (2023)

Adherence and persistence in patients with rheumatoid arthritis at an integrated health system specialty pharmacy
por: Peter, Megan E, et al.
Publicado: (2021)

Refining the Management of Rheumatoid Arthritis: the Benefits of Subcutaneous Tocilizumab
por: Negoescu, Andra F., et al.
Publicado: (2014)

A Potential Benefit of “Balanced Diet” for Rheumatoid Arthritis
por: Masuko, Kayo
Publicado: (2018)

Targeting transcription factors for therapeutic benefit in rheumatoid arthritis
por: Balendran, Thivya, et al.
Publicado: (2023)

Spanish Rheumatology Society and Hospital Pharmacy Society Consensus on recommendations for biologics optimization in patients with rheumatoid arthritis, ankylosing spondylitis and psoriatic arthritis
por: González-Álvaro, Isidoro, et al.
Publicado: (2015)

The Cost-Effectiveness of Biologics for the Treatment of Rheumatoid Arthritis: A Systematic Review
por: Joensuu, Jaana T., et al.
Publicado: (2015)

Quality of Life and Cost Study of Rheumatoid Arthritis Therapy With Biological Medicines
por: Boyadzieva, Vladimira V., et al.
Publicado: (2018)

Pharmacoeconomic evaluation of costs of rheumatoid arthritis therapy with selected biological treatment
por: Kowalik, Krzysztof, et al.
Publicado: (2018)

Knee alterations in rheumatoid arthritis: Comparison of US and MRI
por: Xiao, Lu, et al.
Publicado: (2021)

Cost-effectiveness of adalimumab for rheumatoid arthritis in Germany
por: Gissel, C., et al.
Publicado: (2016)

Analysis of the Indirect Costs of Rheumatoid Arthritis in Romania
por: Codreanu, Cătălin, et al.
Publicado: (2019)

Biologic Drugs for Rheumatoid Arthritis in the Context of Biosimilars, Genetics, Epigenetics and COVID-19 Treatment
por: Bonek, Krzysztof, et al.
Publicado: (2021)

Anticipated efficiencies, real costs: Medicaid managed care organizations and the pharmacy benefit
por: Bendicksen, Liam, et al.
Publicado: (2022)

Analysis of Drug and Administrative Costs Allowed by U.S. Private and Public Third-Party Payers for 3 Intravenous Biologic Agents for Rheumatoid Arthritis
por: Stavrakas, Spyros, et al.
Publicado: (2011)

Platelet-Rich Plasma for Rheumatoid Arthritis: A Case Series
por: Shively, Dana, et al.
Publicado: (2021)

Etanercept‐Methotrexate Combination Therapy Initiators Have Greater Adherence and Persistence Than Triple Therapy Initiators With Rheumatoid Arthritis
por: Bonafede, Machaon, et al.
Publicado: (2015)

Mortality estimates and excess mortality in rheumatoid arthritis
por: Black, Rachel J, et al.
Publicado: (2023)

Burden of rheumatoid arthritis among US Medicare population: co-morbidities, health-care resource utilization and costs
por: Chen, Chieh-I, et al.
Publicado: (2018)

Effectiveness and Costs Among Rheumatoid Arthritis Patients Treated with Targeted Immunomodulators Using Real-World U.S. Data
por: Gharaibeh, Mahdi, et al.
Publicado: (2020)

Durability of Response to Tocilizumab Therapy in Rheumatoid Arthritis: Data from the US-Based Corrona Rheumatoid Arthritis Registry
por: Pappas, Dimitrios A., et al.
Publicado: (2021)

Further evaluation of a claims-based algorithm to determine the effectiveness of biologics for rheumatoid arthritis using commercial claims data
por: Curtis, Jeffrey R, et al.
Publicado: (2013)

Pharmacy cost outliers in primary care; multilevel approach based on ACG in the Spanish context
por: Prados, A, et al.
Publicado: (2008)

Validation of an algorithm to identify incident interstitial lung disease in patients with rheumatoid arthritis
por: Meehan, M., et al.
Publicado: (2022)

Effectiveness and costs of multidisciplinary care in patients with rheumatoid arthritis
por: Verstappen, S.M.M.
Publicado: (2003)

Cannot write session to /tmp/vufind_sessions/sess_nkqtceq4hj147cmv9hssdfddii